Home Drug IndexClinical Monograph

Levetiracetam Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antiepileptic

Subclass

Pyrrolidone derivative

Speciality

Neurology

Schedule (India)

Schedule H

Routes

Oral, Intravenous

Formulations

Tablets (Immediate-Release): 250 mg, 500 mg, 750 mg, 1000 mg
Extended-Release Tablets: 500 mg, 750 mg, 1000 mg
Oral Solution: 100 mg/mL
Injection (IV): 500 mg/5 mL (100 mg/mL)

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Focal (Partial-Onset) Seizures — with or without secondary generalisation

Adults — Monotherapy or Adjunctive Therapy:

Parameter	Recommendation
Starting dose	500 mg orally twice daily
Titration	Increase by 500 mg twice daily every 2 weeks based on response and tolerability
Usual maintenance dose	1000–3000 mg/day in 2 divided doses
Maximum dose	3000 mg/day

Clinical Notes:

May be used as monotherapy or adjunctive therapy
IV formulation bioequivalent to oral — same dose, administer over 15 minutes
Extended-release tablets allow once-daily dosing in stable patients

2. Myoclonic Seizures in Juvenile Myoclonic Epilepsy

Adults — Adjunctive Therapy Only:

Parameter	Recommendation
Starting dose	500 mg orally twice daily
Titration	Increase by 500 mg twice daily every 2 weeks
Usual maintenance dose	1000–3000 mg/day in 2 divided doses
Maximum dose	3000 mg/day

Clinical Notes:

Approved only as adjunctive therapy — not for monotherapy in myoclonic seizures
Age ≥12 years for this indication

3. Primary Generalised Tonic-Clonic Seizures in Idiopathic Generalised Epilepsy

Adults — Adjunctive Therapy:

Parameter	Recommendation
Starting dose	500 mg orally twice daily
Titration	Increase by 500–1000 mg/day every 2–4 weeks
Usual maintenance dose	1000–3000 mg/day in 2 divided doses
Maximum dose	3000 mg/day

Clinical Notes:

Effective for generalised tonic-clonic seizures in idiopathic generalised epilepsy
Age ≥12 years for this indication

4. Intravenous Use — When Oral Administration Not Feasible

Parameter	Recommendation
Dose	Same as oral dosing — 1:1 dose equivalence
Administration	Dilute in NS/D5W/RL and infuse over 15 minutes
Duration of IV use	Transition to oral as soon as feasible

Secondary Indications – Adults Only (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Status Epilepticus — Adjunctive Therapy — OFF-LABEL	Loading: 1000–3000 mg IV over 15 minutes; Maintenance: 500–1500 mg BD	Until seizure control achieved and oral transition possible	Specialist/ICU only	Indian tertiary hospital protocols; supportive RCTs
Post-Traumatic Seizure Prophylaxis — OFF-LABEL	500 mg BD starting within 24 hours of injury	7 days post-injury (short-term prophylaxis only)	Neurosurgery/Critical Care	AIIMS protocols; international RCTs

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications: Focal Seizures, Myoclonic Seizures, Generalised Tonic-Clonic Seizures

Age Restriction: Not recommended below 1 month of age. Use below 6 months only under specialist paediatric neurology supervision.

Weight-Based Dosing Table

Age Group	Starting Dose	Titration	Usual Maintenance	Maximum Dose
1–6 months	7 mg/kg orally twice daily	Increase by 7 mg/kg BD every 2 weeks	21 mg/kg twice daily	42 mg/kg/day
6 months – <4 years	10 mg/kg orally twice daily	Increase by 10 mg/kg BD every 2 weeks	25 mg/kg twice daily	50 mg/kg/day
4 – <16 years	10 mg/kg (max 250 mg) orally twice daily	Increase by 10 mg/kg BD every 2 weeks	30 mg/kg twice daily	60 mg/kg/day (max 3000 mg/day)
≥16 years	Adult dosing applies	—	—	3000 mg/day

Formulation Notes:

Use oral solution (100 mg/mL) for accurate weight-based dosing in younger children
Tablets appropriate for children ≥20 kg who can swallow whole tablets
IV dosing same as oral — infuse over 15 minutes

Safety Monitoring:

Monitor for behavioural changes (irritability, aggression, mood swings)
Assess sedation and psychomotor development
Educate caregivers about behavioural adverse effects

Secondary Indications – Paediatric (Off-label)

Indication	Dose	Notes	Evidence Basis
Adjunctive therapy in Dravet Syndrome — OFF-LABEL	Individualised; often 20–40 mg/kg/day	Specialist only; usually combined with valproate or clobazam	Indian paediatric neurology practice
Neonatal Seizures — OFF-LABEL	Loading: 20–40 mg/kg IV; Maintenance: 10–30 mg/kg BD	NICU setting only; specialist supervision mandatory	Tertiary NICU protocols

Renal Adjustments

Levetiracetam is primarily renally excreted — dose reduction required in renal impairment:

eGFR (mL/min/1.73 m²)	Recommended Dose
≥80	No adjustment — standard dosing
50–79	500–1000 mg twice daily
30–49	250–750 mg twice daily
<30 (not on dialysis)	250–500 mg twice daily
ESRD on haemodialysis	500–1000 mg once daily; give supplemental dose of 250–500 mg after each dialysis session

Notes:

Use oral solution for precise dose titration in severe impairment
Peritoneal dialysis: limited data; use haemodialysis recommendations as guide

Hepatic adjustment

Contraindications

Known hypersensitivity to levetiracetam, other pyrrolidone derivatives, or any excipient
History of severe psychiatric reaction (psychosis, severe aggression) attributable to levetiracetam — relative contraindication; avoid rechallenge

Cautions

Pre-existing psychiatric disorders (depression, anxiety, psychosis) — risk of exacerbation
History of behavioural disturbances — increased risk of irritability and aggression
Suicidal ideation risk — monitor mood, especially in adolescents and young adults
Renal impairment — dose adjustment mandatory
Elderly with cognitive impairment — enhanced CNS sensitivity
Abrupt withdrawal — taper gradually over 2–4 weeks to avoid rebound seizures
Driving and operating machinery — advise caution due to somnolence risk

Pregnancy

Parameter	Details
Risk category	Relatively low teratogenic risk compared to older AEDs (valproate, phenytoin, carbamazepine)
Preferred alternatives	Levetiracetam or lamotrigine preferred in Indian obstetric/neurology practice when AED required
When may be used	May be continued in pregnancy if seizure control established; avoid switching AEDs during pregnancy if possible
Monitoring	Folic acid 5 mg/day from preconception through first trimester; monitor maternal seizure control; targeted anomaly scan; monitor drug levels (clearance increases in pregnancy)
Neonatal concerns	Monitor neonate for withdrawal symptoms (rare); vitamin K prophylaxis as standard

Lactation

Parameter	Details
Compatibility	Compatible with breastfeeding
Drug levels in milk	Low to moderate (infant receives approximately 3–8% of maternal weight-adjusted dose)
Preferred alternatives	Levetiracetam is among preferred AEDs for lactating women; lamotrigine also acceptable
Infant monitoring	Observe for sedation, irritability, poor feeding, weight gain; monitor developmental milestones

Elderly

Parameter	Recommendation
Starting dose	250 mg twice daily
Titration	Slower titration — increase by 250 mg twice daily every 2 weeks
Special risks	Increased risk of somnolence, dizziness, falls, cognitive impairment; higher prevalence of occult renal impairment — check eGFR before dosing
Formulation	Oral solution preferred for flexible dose adjustment

Major drug interactions

Drug/Class	Mechanism/Effect	Recommendation
Methotrexate	Levetiracetam may reduce renal clearance of methotrexate → increased methotrexate toxicity	Monitor for methotrexate toxicity (mucositis, myelosuppression); consider dose adjustment
CNS depressants (benzodiazepines, opioids, sedating antihistamines)	Additive CNS depression	Use cautiously; monitor for excessive sedation

Note: Levetiracetam does not induce or inhibit CYP450 enzymes — minimal hepatic drug interaction potential.

Moderate drug interactions

Drug/Class	Effect	Recommendation
Carbamazepine	Minor pharmacokinetic interaction; possible slight increase in carbamazepine-epoxide	Monitor for carbamazepine toxicity symptoms (diplopia, ataxia)
Other antiepileptics (valproate, phenytoin, phenobarbital)	No significant pharmacokinetic interactions; may have additive CNS effects	Standard monitoring; generally safe combination
Warfarin	Theoretical interaction (not CYP-mediated)	Monitor INR when initiating or stopping levetiracetam
Antidepressants/Antipsychotics	Additive risk of behavioural adverse effects	Monitor mood and behaviour closely
Oral contraceptives	No enzyme induction — does not reduce contraceptive efficacy	Safe combination; no additional contraception required

Common Adverse effects

Somnolence / drowsiness
Dizziness
Asthenia / fatigue
Irritability and behavioural changes
Headache
Nasopharyngitis / upper respiratory infections
Decreased appetite
Mood changes (anxiety, emotional lability)

Serious Adverse effects'

Adverse Effect	Clinical Action
Severe behavioural disturbance (psychosis, aggression, hostility)	Consider dose reduction or discontinuation; psychiatric evaluation
Suicidal ideation or behaviour	Immediate psychiatric referral; consider drug discontinuation
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis	Immediate discontinuation and hospitalisation — rare but reported
Anaphylaxis / Angioedema	Discontinue immediately; emergency management
DRESS syndrome	Rare; discontinue and supportive care
Pancytopenia / Agranulocytosis	Very rare; discontinue and investigate
Rhabdomyolysis	Rare; check CK if myalgia/weakness prominent

Monitoring requirements

Baseline:

Renal function (serum creatinine, eGFR)
Seizure history and frequency documentation
Psychiatric history assessment
Pregnancy test in women of childbearing age

After Initiation / Dose Change:

Mental status and behavioural assessment at 2–4 weeks
Seizure frequency monitoring
Assessment for irritability, mood changes (especially in children and adolescents)
Evaluate for somnolence and cognitive effects

Long-term Monitoring:

Renal function annually (more frequently in elderly or renal impairment)
Behavioural and mood assessment at each visit
Growth parameters in children
Seizure diary review
Periodic assessment of need for continued therapy

Note: Routine serum drug level monitoring not required — clinical response guides dosing. Therapeutic drug monitoring may be considered in pregnancy, renal impairment, or suspected non-adherence.

Brands in India

Single-Ingredient Formulations:

Keppra (UCB)
Levipil (Sun Pharma)
Torleva (Torrent)
Levera (Intas)
Levesam (Mankind)
Levroxa (Macleods)
Epitero (Cipla)
Levegard (Zydus)

Extended-Release Formulations:

Levipil XR (Sun Pharma)
Torleva XR (Torrent)

IV Formulations:

Keppra IV (UCB)
Levipil IV (Sun Pharma)

Price range (INR)

Formulation	Approximate Price
Tablet 250 mg (per tablet)	₹3–₹8
Tablet 500 mg (per tablet)	₹5–₹15
Tablet 750 mg (per tablet)	₹8–₹18
Tablet 1000 mg (per tablet)	₹10–₹22
Oral Solution 100 mL	₹150–₹300
Injection 500 mg/5 mL (per vial)	₹100–₹250
Extended-Release tablets (per tablet)	₹12–₹30

Not currently included in NLEM 2022
Available in government hospitals through neurology programmes
Significant brand-to-brand price variation — generic options more affordable

Clinical pearls

Preferred AED in hepatic impairment — minimal hepatic metabolism makes levetiracetam ideal for patients with liver disease or those on multiple hepatically metabolised drugs
No enzyme induction — unlike carbamazepine and phenytoin, does not reduce efficacy of oral contraceptives, warfarin, or other CYP-metabolised drugs
Behavioural adverse effects are common — especially irritability and aggression in children; counsel caregivers at initiation and monitor closely; pyridoxine (vitamin B6) supplementation sometimes used empirically to mitigate behavioural effects
Seamless IV-to-oral transition — bioequivalent formulations allow direct 1:1 dose conversion without adjustment
Gradual withdrawal essential — even in seizure-free patients, abrupt discontinuation may precipitate rebound seizures; taper over 2–4 weeks minimum
Pregnancy-compatible AED — among the safer antiepileptics for use during pregnancy; preferred over valproate, phenytoin, and carbamazepine when new AED initiation required in women of childbearing potential
Renal dosing mandatory in elderly — age-related decline in renal function often unrecognised; always calculate eGFR before prescribing

Version

RxIndia v1.0 — 05 Jun 2025

Reference

- CDSCO approved product inserts
- Indian Pharmacopoeia
- API Textbook of Medicine
- AIIMS Epilepsy Management Protocol
- ICMR Guidelines on Neurological Disorders
- IAP Paediatric Drug Formulary
- Indian Epilepsy Society recommendations
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)
- Harrison's Principles of Internal Medicine (supportive)
- International RCTs for off-label status epilepticus use

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...